Company Description
ADMA Biologics, Inc., a commercial biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
It also develops a pipeline of plasma-derived therapeutics. In addition, the company operates source plasma collection facilities, including collections of source plasma, procurement of raw materials and packaging materials, and the testing of finished drug products.
The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers.
ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 685 |
| CEO | Adam Grossman |
Contact Details
Address: 465 State Route 17 Ramsey, New Jersey 07446 United States | |
| Phone | 201 478 5552 |
| Website | admabiologics.com |
Stock Details
| Ticker Symbol | ADMA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001368514 |
| CUSIP Number | 000899104 |
| ISIN Number | US0008991046 |
| Employer ID | 56-2590442 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Adam S. Grossman | Co-Founder, President, Chief Executive Officer and Director |
| Dr. Jerrold B. Grossman D.P.S., Ph.D. | Co-Founder and Vice Chairman of the Board |
| Brad Tade | Chief Financial Officer and Treasurer |
| Kaitlin Kestenberg | Chief Operating Officer and Senior Vice President of Compliance |
| Drew Pantello | Vice President of Marketing and Corporate Development |
| John Hafl | Executive Director of Sales |
| Cindy Petersen | Vice President of Human Resources |
| Skyler Bloom | Senior Director of Business Development and Corporate Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 19, 2025 | 144 | Filing |
| Mar 18, 2025 | 10-K | Annual Report |
| Mar 3, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 21, 2025 | 8-K | Current Report |
| Feb 7, 2025 | SCHEDULE 13G/A | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 2, 2025 | 8-K | Current Report |
| Dec 20, 2024 | 8-K | Current Report |